US-based Isis Pharma has signed a drug development deal with Biogen Idec, relating to the development of medication to treat spinal muscular atrophy.
The drug, ISIS-SMNRx, was discovered by Isis and is currently being used in a Phase I clinical trial, which started in December 2011.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As per the terms of the deal, Isis will receive an initial payment of $29m, followed by milestone payments of up to $45m. Biogen will retain the option on the license for the drug up until the first successful Phase II/III trial which, if exercised, could see Isis receive up to $225m in licence regulatory milestone payments, taking the potential total up to $299m.
Isis will continue to play the lead role in the drugs development up until the completion of Phase II/III clinical trials, with Biogen providing advice on the design of trials and how to appease strict US Food and Drug Administration stipulations.
Spinal muscular atrophy is a genetic disease that causes progressive muscle degeneration and can lead to early death in severe cases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
